AsiaOne Magazine April-May 2018 Issue
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Iconic<br />
healthcare<br />
Mundipharma<br />
Making Great Strides towards the Welfare of Humanity<br />
Pioneering healthcare for humanity, Mundipharma is bent on its mission of making<br />
innovative medicines accessible to all those in need. Under the quintessential<br />
leadership of Mr. Raman Singh, it has emerged as one of the fastest growing<br />
pharmaceutical businesses in the world<br />
Efficiently spearheaded<br />
by CEO, Mr. Raman<br />
Singh, a highly<br />
experienced<br />
healthcare veteran who brings in<br />
more than 2 decades of industry<br />
experience, Mundipharma<br />
is consistently setting new<br />
benchmarks of success in<br />
the pharmaceutical industry.<br />
Focused on transforming<br />
Mundipharma’s business, he<br />
has played a significant role<br />
in dramatically increasing the<br />
size of the organization in terms<br />
of its geographic footprint,<br />
number of employees, portfolio<br />
of medicines and performance.<br />
Prioritizing Patients<br />
Even though the firm has<br />
achieved 24 consecutive<br />
quarters of growth, yet at<br />
the same time, Mundipharma<br />
abides by its core value of<br />
keeping patients at the heart<br />
of everything it does. The<br />
geographic expansion – from<br />
operating in 12 countries to<br />
now having a presence in<br />
over 120 – indicates that the<br />
organization touches the lives<br />
of more patients than ever<br />
before. Mundipharma entities<br />
cover pharmaceutical markets<br />
in Asia-Pacific, Latin America,<br />
Middle East and Africa.<br />
The headquarters for these<br />
territories is in Singapore.<br />
With a mission of alleviating<br />
the suffering of patients and<br />
to substantially improve their<br />
quality of life, Mundipharma is<br />
dedicated to bringing to patients<br />
the benefit of novel treatment<br />
options in fields such as pain,<br />
oncology, oncology supportive<br />
care, ophthalmology,<br />
respiratory disease &consumer<br />
healthcare.<br />
The organisation’s R&D is<br />
led from research centres in<br />
Singapore, USA, UK, Germany,<br />
China and Japan and it carries<br />
out pre-clinical research,<br />
pharmaceutical development,<br />
clinical development, drug<br />
safety, regulatory affairs<br />
& scientific support of new<br />
treatments. Mundipharma<br />
also leverages a network of<br />
world-class manufacturing<br />
facilities & benefits from<br />
vertical integration, which<br />
in turn benefits patients.<br />
Currently, the firm is in the<br />
process of opening a new<br />
global R&D, manufacturing &<br />
distribution facility in Singapore<br />
for its range of consumer<br />
healthcare products that sit<br />
under the umbrella of the iconic<br />
BETADINE® brand.<br />
Mr. Singh believes that by<br />
fully harnessing the power of<br />
innovative new technology,<br />
Mundipharma will be able<br />
to help even more patients.<br />
Thus, Mundipharma launched<br />
breatheriteTM, an innovative<br />
mobile app that employs<br />
augmented reality technology<br />
to address errors in inhaler<br />
use among Asthma sufferers.<br />
176 | ASIA ONE | april-mAY <strong>2018</strong>
Change language